World Journal of Cardiology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Homepage

Online Submission

Number of total visits: 1537528

Number of visits today: 454

Number of downloads: 787235

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Vilain KA, Yang MC, Hui Tan EC, Wang K, Li H, Hsu WH, Giugliano RP, Cohen DJ, Magnuson EA; ENGAGE AF – TIMI 48 Investigators. Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective. Value Health Reg Issues 2017;12:74-83. [PMID: 28648320 DOI: 10.1016/j.vhri.2017.03.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]

For:

Vilain KA, Yang MC, Hui Tan EC, Wang K, Li H, Hsu WH, Giugliano RP, Cohen DJ, Magnuson EA; ENGAGE AF – TIMI 48 Investigators. Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective. Value Health Reg Issues 2017;12:74-83. [PMID: 28648320 DOI: 10.1016/j.vhri.2017.03.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]

Number	Citing Articles
1	Azahar SN, Sulong S, Wan Zaidi WA, Muhammad N, Kamisah Y, Masbah N. Direct Medical Cost of Stroke and the Cost-Effectiveness of Direct Oral Anticoagulants in Atrial Fibrillation-Related Stroke: A Cross-Sectional Study. IJERPH 2022;19:1078. [DOI: 10.3390/ijerph19031078] [Reference Citation Analysis]
2	Liao CT, Lee MC, Chen ZC, Ku LE, Wang JD, Toh HS. Cost-Effectiveness Analysis of Oral Anticoagulants in Stroke Prevention among Patients with Atrial Fibrillation in Taiwan. Acta Cardiol Sin 2020;36:50-61. [PMID: 31903008 DOI: 10.6515/ACS.202001_36(1).20190511A] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
3	Cervantes CE, Merino JL, Barrios V. Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 2019;17:319-30. [DOI: 10.1080/14779072.2019.1598263] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
4	Lekuona I, Anguita M, Zamorano JL, Rodríguez JM, Barja de Soroa P, Pérez-Alcántara F. Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain? Rev Esp Cardiol (Engl Ed) 2019;72:398-406. [PMID: 31007166 DOI: 10.1016/j.rec.2018.03.024] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5	Noviyani R, Youngkong S, Nathisuwan S, Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, McKay G, Sritara P, Attia J, Thakkinstian A. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. BMJ Evid Based Med 2021:bmjebm-2020-111634. [PMID: 34635480 DOI: 10.1136/bmjebm-2020-111634] [Reference Citation Analysis]
6	Wang KL, Chiang CE. Health Economics of Stroke Prevention in Atrial Fibrillation. Acta Cardiol Sin 2020;36:62-3. [PMID: 31903009 DOI: 10.6515/ACS.202001_36(1).20191212A] [Reference Citation Analysis]